Speedel Group Release: SPP100 (Tekturna/Rasilex) Reduces Left Ventricular Hypertrophy
4/1/2008 9:31:18 AM
More...
|
Speedel Group Holds Annual R&D Day
3/31/2008 11:17:50 AM
More...
|
Speedel Group Announces A New Series Of Renin Inhibitors
2/16/2006 11:13:20 AM
More...
|
Speedel Group Release: SPP301 Phase IIb Results In Diabetic Nephropathy Presented At ASN
11/14/2005 10:39:21 AM
More...
|
Speedel Brings In CHF47.8M To Advance Pipeline Projects
10/19/2005 5:12:49 PM
More...
|
Speedel Raises CHF 47.8 Million In Private Funding Round
10/19/2005 5:12:47 PM
More...
|
Novartis' (NVS) Latest Phase III And II Data With SPP100 (Aliskiren) Reconfirm Speedel's Previous Clinical Studies For The Treatment Of Hypertension
10/19/2005 5:12:31 PM
More...
|
Professor Karl-Heinz Altmann Joins Speedel Scientific & Technical Advisory Board
10/19/2005 5:12:16 PM
More...
|
Speedel Group Release: Successful Outcome Of Aliskiren, The First-In-Class Renin Inhibitor, Vs. Irbesartan, In A 650 Patient Hypertension Study, Recently Completed By Novartis (NVS)
10/19/2005 5:10:49 PM
More...
|
Speedel Pharmaceuticals, Inc. Appoints Rolf Hanggi To Board Of Directors
10/19/2005 5:10:27 PM
More...
|
|